Processa (PCSA) R&D head buys 1,545 shares at $2.97 in open market

Rhea-AI Filing Summary

Processa Pharmaceuticals director and Pres. Research & Development David Young reported an open-market purchase of 1,545 shares of common stock at $2.97 per share on May 15, 2026. After this trade, he directly holds 15,345 common shares.

The filing also reports indirect holdings of 742 shares through CorLyst, LLC, 432 shares through family entities, and 1,242 shares through the Young-Plaisance Revocable Trust as of the same date. A footnote states that share amounts were adjusted to correct immaterial errors in a prior Form 4, including a corrected April 30, 2026 purchase price of $2.71 per share instead of $2.69, which reduced that earlier purchase by 13 shares.

Insider Trade Summary

Net Buyer: 1,545 shares ($4,589)

Net Buy 4 txns

Insider Young David

Role Pres. Research & Development

Bought 1,545 shs ($5K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,545	$2.97	$5K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 15,345 shares (Direct, null); Common Stock — 1,242 shares (Indirect, By Young-Plaisance Revocable Trust)

Footnotes (1)

1. [object Object]

Key Figures

Shares purchased: 1,545 shares Purchase price: $2.97 per share Direct holdings after transaction: 15,345 shares +5 more

8 metrics

Shares purchased 1,545 shares Open-market purchase on May 15, 2026

Purchase price $2.97 per share Open-market buy on May 15, 2026

Direct holdings after transaction 15,345 shares Common stock directly owned after May 15, 2026 trade

Indirect holdings via CorLyst, LLC 742 shares Indirect ownership as reported on May 15, 2026

Indirect holdings via family entities 432 shares Indirect ownership as reported on May 15, 2026

Indirect holdings via revocable trust 1,242 shares Indirect ownership via Young-Plaisance Revocable Trust

Corrected prior purchase price $2.71 per share April 30, 2026 transaction corrected from $2.69

Reduction in prior shares 13 shares Adjustment to April 30, 2026 purchase

Key Terms

open-market purchase, indirect ownership, revocable trust, Form 4, +1 more

5 terms

open-market purchase financial

"Purchase in open market or private transaction"

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

indirect ownership financial

"Reported as indirect ownership by CorLyst, LLC and family entities"

revocable trust financial

"By Young-Plaisance Revocable Trust"

A revocable trust is a legal arrangement where the person who creates it keeps control and can change or cancel the trust at any time, while naming who will manage and receive the assets later. Think of it like a flexible folder for your investments and property that can be relabeled or reworked as circumstances change; it matters to investors because it determines how ownership is recorded, how easily assets transfer on incapacity or death, and whether holdings bypass public probate proceedings.

Form 4 regulatory

"errors made on the Form 4 filed on May 1, 2026"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

price per share financial

"The corrected price per share for the purchase made on April 30, 2026 is $2.71"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Young David

(Last) (First) (Middle)

C/O PROCESSA PHARMACEUTICALS, INC.

601 21ST STREET SUITE 300

(Street)

VERO BEACH FLORIDA 32960

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Processa Pharmaceuticals, Inc. [ PCSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Pres. Research & Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/15/2026		P		1,545	A	$2.97	15,345(1)	D
Common Stock								1,242	I	By Young-Plaisance Revocable Trust
Common Stock								432	I	By Family Entities
Common Stock								742	I	By CorLyst, LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares adjusted to correct immaterial errors made on the Form 4 filed on May 1, 2026. The corrected price per share for the purchase made on April 30, 2026 is $2.71, not $2.69, which reduces the amount purchased on April 30, 2026 by 13 shares.

	/s/ David Young by John J. Wolfel, as Attorney-in-Fact	05/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did David Young report for Processa Pharmaceuticals (PCSA)?

David Young reported buying 1,545 shares of Processa common stock in an open-market transaction at $2.97 per share. This Form 4 filing reflects his latest direct purchase and updates his reported ownership position in the company’s shares.

How many Processa (PCSA) shares does David Young hold after this Form 4 transaction?

After the May 15, 2026 purchase, David Young directly owns 15,345 shares of Processa common stock. The filing also lists indirect holdings through CorLyst, LLC, family entities, and the Young-Plaisance Revocable Trust, each reported separately.

At what price did David Young buy Processa Pharmaceuticals (PCSA) shares?

David Young’s May 15, 2026 open-market purchase was executed at $2.97 per share. The Form 4 further corrects a prior April 30, 2026 purchase price to $2.71 per share, instead of the previously reported $2.69.

What indirect holdings of Processa (PCSA) stock are reported for David Young?

The Form 4 lists 742 shares held through CorLyst, LLC, 432 shares held by family entities, and 1,242 shares held by the Young-Plaisance Revocable Trust. These positions are reported as indirect ownership, separate from his direct shareholdings.

Does the Processa (PCSA) Form 4 include corrections to earlier filings?

Yes. A footnote explains that share amounts were adjusted to correct immaterial errors in a Form 4 filed May 1, 2026. It revises the April 30, 2026 purchase price to $2.71 per share and reduces that purchase by 13 shares.

What is the net effect of David Young’s latest Form 4 on his Processa (PCSA) position?

The latest Form 4 adds an open-market purchase of 1,545 shares at $2.97, increasing his direct holdings to 15,345 shares. It also updates previously reported figures to correct small errors in the earlier Form 4.